Ticker Details
BioCryst Pharmaceuticals, Inc. Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
IPO Date:	March 4, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.44B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 3.37%
Avg Daily Range (30 D):	$0.23 | 2.31%
Avg Daily Range (90 D):	$0.22 | 2.39%

Institutional Daily Volume
Avg Daily Volume:	1.65M
Avg Daily Volume (30 D):	2.74M
Avg Daily Volume (90 D):	3.71M

Trade Size
Avg Trade Size (Sh.):	175
Avg Trade Size (Sh.) (30 D):	101
Avg Trade Size (Sh.) (90 D):	126

Institutional Trades
Total Institutional Trades:	4,460
Avg Institutional Trade:	$2.32M
Avg Institutional Trade (30 D):	$3.24M
Avg Institutional Trade (90 D):	$2.93M
Avg Institutional Trade Volume:	.28M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.38M
Avg Closing Trade (30 D):	$4.94M
Avg Closing Trade (90 D):	$6.07M
Avg Closing Volume:	407.39K

News

Jun 12, 2026 @ 11:00 AM BioCryst Presents New Clinical Data and Real-World... Source: Biocryst Pharmaceuticals, Inc.

May 6, 2026 @ 11:00 AM BioCryst Reports First Quarter 2026 Financial Resu... Source: Biocryst Pharmaceuticals, Inc.

May 4, 2026 @ 11:00 AM BioCryst Announces European Licensing Agreement wi... Source: Na

Apr 6, 2026 @ 11:00 AM BioCryst Appoints Sandeep M. Menon Chief Research ... Source: Biocryst Pharmaceuticals, Inc.

Mar 4, 2026 @ 12:00 PM BioCryst Reports Inducement Grants Under Nasdaq Li... Source: Globe Newswire

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.44	$.31	$-2.98
Diluted EPS	$-1.49	$.3	$-2.98
Revenue	$940.61M	$218.25M	$156.41M
Gross Profit	$919.69M	$214.41M	$151.04M
Net Income / Loss	$-384.67M	$78.4M	$-721.81M
Operating Income / Loss	$-313.16M	$98.47M	$-701.6M
Cost of Revenue	$20.93M	$3.84M	$5.38M
Net Cash Flow	$51.4M	$-16.99M	$82.04M
PE Ratio